Floatz logo

Xifaxan

Primary Sclerosing Cholangitis (PSC)

Mayo ClinicPhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

22 Active assets in the Primary Sclerosing Cholangitis (PSC) cohort.

Asset / SponsorPhaseRating
Vancomycin
Tampere University Hospital
Phase 4BB
URSODEOXYCHOLIC ACID
Assistance Publique - Hôpitaux de Paris
Phase 3BB
Elafibranor
Ipsen
Phase 3B
Aldafermin
NGM Biopharmaceuticals, Inc
Phase 2/3B
cm-101
ChemomAb Ltd.
Phase 2B

View all 50 →

Same molecule, other indications

Xifaxan is also rated in:

Chronic Abdominal PainDormant
D
Indicative ·
30 / 100
View asset →
small intestinal bacterial overgrowthDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →